Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of $1.58, $0.15 better than the analyst estimate of $1.43. Revenue for the quarter came in at $149.7 million versus the consensus estimate of $148.02 million.

GUIDANCE:

Collegium Pharma sees FY2024 revenue of $580-595 million, versus the consensus of $582.9 million.

Adjusted Operating Expenses(Excluding Stock-Based Compensation) $120.0 to $125.0 million

Adjusted EBITDA(Excluding Stock-Based Compensation) $380.0 to $395.0 million

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.